Literature DB >> 27859518

Ixazomib cardiotoxicity: A possible class effect of proteasome inhibitors.

Hayan Jouni1, Mary C Aubry2, Martha Q Lacy3, S Vincent Rajkumar3, Shaji K Kumar3, Robert L Frye1, Joerg Herrmann1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27859518     DOI： 10.1002/ajh.24608

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  8 in total

Review 1.  Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention.

Authors:  Dae Hyun Lee; Michael G Fradley
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-06

2.  A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

Authors:  Jacob P Laubach; Javid J Moslehi; Sanjeev A Francis; Jesús F San Miguel; Pieter Sonneveld; Robert Z Orlowski; Philippe Moreau; Laura Rosiñol; Edward A Faber; Peter Voorhees; Maria-Victoria Mateos; Loreta Marquez; Huaibao Feng; Avinash Desai; Helgi van de Velde; Jennifer Elliott; Hongliang Shi; Edward Dow; Nishith Jobanputra; Dixie-Lee Esseltine; Liviu Niculescu; Kenneth C Anderson; Sagar Lonial; Paul G Richardson
Journal:  Br J Haematol       Date:  2017-05-03       Impact factor: 6.998

Review 3.  Cardiovascular Imaging in Cardio-Oncology: The Role of Echocardiography and Cardiac MRI in Modern Cardio-Oncology.

Authors:  John Alan Gambril; Aaron Chum; Akash Goyal; Patrick Ruz; Katarzyna Mikrut; Orlando Simonetti; Hardeep Dholiya; Brijesh Patel; Daniel Addison
Journal:  Heart Fail Clin       Date:  2022-07       Impact factor: 2.828

4.  Bortezomib-Induced Cardiac Tamponade in a 49-Year-Old Man.

Authors:  Taylor Burkhart; Matthew Cody Lee Keith; Carrie Ann Geisberg Lenneman; Rajeev Ruben Fernando
Journal:  Tex Heart Inst J       Date:  2018-08-01

Review 5.  Long non-coding RNAs and microRNAs as crucial regulators in cardio-oncology.

Authors:  Sarath Babu Nukala; Jordan Jousma; Yoonje Cho; Won Hee Lee; Sang-Ging Ong
Journal:  Cell Biosci       Date:  2022-03-04       Impact factor: 7.133

6.  Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS).

Authors:  Benjamin Buck; Eric Kellett; Daniel Addison; Ajay Vallakati
Journal:  J Saudi Heart Assoc       Date:  2022-08-31

Review 7.  Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).

Authors:  Sara Bringhen; Alberto Milan; Claudio Ferri; Ralph Wäsch; Francesca Gay; Alessandra Larocca; Marco Salvini; Evangelos Terpos; Hartmut Goldschmidt; Michele Cavo; Maria Teresa Petrucci; Heinz Ludwig; Holger W Auner; Jo Caers; Martin Gramatzki; Mario Boccadoro; Hermann Einsele; Pieter Sonneveld; Monika Engelhardt
Journal:  Haematologica       Date:  2018-07-26       Impact factor: 9.941

Review 8.  Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity.

Authors:  Carmine Rocca; Ernestina Marianna De Francesco; Teresa Pasqua; Maria Concetta Granieri; Anna De Bartolo; Maria Eugenia Gallo Cantafio; Maria Grazia Muoio; Massimo Gentile; Antonino Neri; Tommaso Angelone; Giuseppe Viglietto; Nicola Amodio
Journal:  Biomedicines       Date:  2022-02-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.